New hope against a deadly parasite: LXE408 trial shows promise
NCT ID NCT05957978
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug called LXE408 in 52 adults with visceral leishmaniasis, a serious parasitic disease. The goal was to see if LXE408 could cure the infection by Day 28 compared to the standard treatment. The trial took place in Ethiopia and measured safety, drug levels, and how well the drug worked.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY VISCERAL LEISHMANIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Gondar
Gonder, Ethiopia
More trials for these conditions
Other studies related to the condition(s) this trial covers.